Etanercept downregulates the th17 pathway and decreases the IL-17 +/IL-10+ cell ratio in patients with psoriasis vulgaris

Journal of Clinical Immunology

Volumn 32, Issue 6, 2012, Pages 1221-1232

  Antiga, Emiliano ^a   Volpi, Walter ^a   Cardilicchia, Elisa ^a   Maggi, Laura ^a   Filì, Lucia ^a   Manuelli, Cinzia ^a   Parronchi, Paola ^a   Fabbri, Paolo ^a   Caproni, Marzia ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

acitretin; etanercept; IL 10+ cells; Psoriasis; T helper 17 cells

Indexed keywords

ETANERCEPT; ETRETIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 8; IL10 PROTEIN, HUMAN; IMMUNOGLOBULIN G; KERATOLYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; BLOOD ANALYSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; DRUG MECHANISM; FEMALE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PSORIASIS VULGARIS; SIGNAL TRANSDUCTION; SKIN BIOPSY; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL; UPREGULATION; BLOOD; DRUG ADMINISTRATION; DRUG EFFECT; GENETICS; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; MIDDLE AGED; PATHOLOGY; PSORIASIS; SKIN; TREATMENT OUTCOME;

ACITRETIN; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CD8-POSITIVE T-LYMPHOCYTES; DERMATITIS, ATOPIC; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-10; INTERLEUKIN-17; KERATOLYTIC AGENTS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; SKIN; TH1 CELLS; TH17 CELLS; TH2 CELLS; TREATMENT OUTCOME;

EID: 84873823762     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-012-9716-x     Document Type: Article

References (40)

1. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445:866-73.
2. Boyman O, Conrad C, Tonel G, Gilliet M, Nestle FO. The pathogenic role of tissue-resident immune cells in psoriasis. Trends Immunol. 2007;28:51-7.
3. Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol. 1994;102:145-9.
4. Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199:125-30.
5. Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suárez-Fariñas M, Fuentes-Duculan J, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204:3183-94.
6. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445:648-51.
7. Lo YH, Torii K, Saito C, Furuhashi T, Maeda A, Morita A. Serum IL-22 correlates with psoriatic severity and serum IL-6 correlates with susceptibility to phototherapy. J Dermatol Sci. 2010;58:225-7.
8. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Abello MV, Novitskaya I, Pierson KC, et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol. 2009;129:79-88.
9. Tonel G, Conrad C, Laggner U, Di Meglio P, Grys K, McClanahan TK, et al. Cutting edge: A critical functional role for IL-23 in psoriasis. J Immunol. 2010;185:5688-91.
10. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S. Human Th17 cells: are they different from murine Th17 cells? Eur J Immunol. 2009;39:637-40.
11. Sallusto F, Lanzavecchia A. Human Th17 cells in infection and autoimmunity. Microbes Infect. 2009;11:620-4.
12. Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol. 2010;130:1373-83.
13. Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128:1207-11.
14. Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest. 2009;119:3573-85.
15. Chen L, Shen Z, Wang G, Fan P, Liu Y. Dynamic frequency of CD4 + CD25 + Foxp3+ Treg cells in psoriasis vulgaris. J Dermatol Sci. 2008;51:200-3.
16. Sugiyama H, Gyulai R, Toichi E, Garaczi E, Shimada S, Stevens SR, et al. Dysfunctional blood and target tissue CD4 + CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol. 2005;174:164-73.
17. Fujio K, Okamura T, Yamamoto K. The Family of IL-10-secreting CD4+ T cells. Adv Immunol. 2010;105:99-130.
18. Chong BF, Wong HK. Immunobiologics in the treatment of psoriasis. Clin Immunol. 2007;123:129-38.
19. Antiga E, Volpi W, Chiarini C, Cardilicchia E, Filì L, Manuelli C, et al. The role of etanercept on the expression of markers of T helper 17 cells and their precursors in skin lesions of patients with psoriasis vulgaris. Int J Immunopathol Pharmacol. 2010;23:767-74.
20. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, et al. Phenotypic and functional features of human Th17 cells. J Exp Med. 2007;204:1849-61.
21. Caproni M, Antiga E, Melani L, Volpi W, Del Bianco E, Fabbri P. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol. 2009;29:210-4.
22. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735-41.
23. Hänsel A, Günther C, Ingwersen J, Starke J, Schmitz M, Bachmann M, et al. Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17/TH1 T-cell responses. J Allergy Clin Immunol. 2011;127:787-94.e1-9.
24. Zhang L, Yang XQ, Cheng J, Hui RS, Gao TW. Increased Th17 cells are accompanied by FoxP3(+) Treg cell accumulation and correlated with psoriasis disease severity. Clin Immunol. 2010;135:108-17.
25. Res PC, Piskin G, de Boer OJ, van der Loos CM, Teeling P, Bos JD, et al. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One. 2010;5:e14108.
26. Kryczek I, Bruce AT, Gudjonsson JE, Johnston A, Aphale A, Vatan L, et al. Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol. 2008;181:4733-41.
27. Quaglino P, Ortoncelli M, Comessatti A, Ponti R, Novelli M, Bergallo M, et al. Circulating CD4+CD25 bright FOXP3+ T cells are up-regulated by biological therapies and correlate with the clinical response in psoriasis patients. Dermatology. 2009;219:250-8.
28. Diluvio L, Romiti ML, Angelini F, Campione E, Rossi P, Prinz JC, et al. Infliximab therapy induces increased polyclonality of CD4 + CD25+ regulatory T cells in psoriasis. Br J Dermatol. 2010;162:895-7.
29. Yun WJ, Lee DW, Chang SE, Yoon GS, Huh JR, Won CH, et al. Role of CD4CD25FOXP3 regulatory T cells in psoriasis. Ann Dermatol. 2010;22:397-403.
30. Quaglino P, Bergallo M, Ponti R, Barberio E, Cicchelli S, Buffa E, et al. Th1, Th2, Th17 and regulatory T cell pattern in psoriatic patients: modulation of cytokines and gene targets induced by etanercept treatment and correlation with clinical response. Dermatology. 2011;223:57-67.
31. Zaba LC, Suárez-Fariñas M, Fuentes-Duculan J, Nograles KE, Guttman-Yassky E, Cardinale I, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol. 2009;124:1022-10.e1-395.
32. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell linear. Annu Rev Immunol. 2007;25:821-52.
33. Sutton C, Brereton C, Keogh B, Mills KH, Lavelle EC. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med. 2006;203:1685-91.
34. Biton J, Semerano L, Delavallée L, Lemeiter D, Laborie M, Grouard-Vogel G, et al. Interplay between TNF and regulatory T cells in a TNF-driven murine model of arthritis. J Immunol. 2011;186:3899-910.
35. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFa therapy. J Exp Med. 2004;200:277-85.
36. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-a therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-b. J Exp Med. 2007;204:33-9.
37. Duan H, Koga T, Kohda F, Hara H, Urabe K, Furue M. Interleukin-8-positive neutrophils in psoriasis. J Dermatol Sci. 2001;26:119-24.
38. Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A, et al. Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-α levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy. Br J Dermatol. 2010;163:1282-90.
39. Pietrzak AT, Zalewska A, Chodorowska G, Krasowska D, Michalak-Stoma A, Nockowski P, et al. Cytokines and anticytokines in psoriasis. Clin Chim Acta. 2008;394:7-21.
40. Fisher GJ, Voorhees JJ. Molecular mechanisms of retinoid actions in skin. FASEB J. 1996;10:1002-13.